Tapinarof Improved Outcomes and Sleep for Patients and Families in Two Phase 3 Atopic Dermatitis Trials in Adults and Children

By sjmartinez • January 9, 2025

Simpson EL, Hebert AA, Browning J, Serrao RT, Sofen H, Brown PM, Piscitelli SC, Rubenstein DS, Tallman AM. Tapinarof Improved Outcomes and Sleep for Patients and Families in Two Phase 3 Atopic Dermatitis Trials in Adults and Children. Dermatol Ther (Heidelb). 2025 Jan 7. doi: 10.1007/s13555-024-01318-6. Epub ahead of print. PMID: 39777610.

Tags: atopic dermatitis, Dermatology, Family impact, Olive View DoM, patient-reported outcomes, Publications, Quality of Life, Sleep improvement, Tapinarof cream 1% once daily, Topical aryl hydrocarbon receptor agonist

Temporal CRAC channel blockade modulates the MYC-MXD axis to attenuate autoimmune inflammation

Wu B, Hasiakos S, Cokus S, Do M, Kaplan E, Pellegrini M, Sun Z, Kim RH, Srikanth S, Gwack Y. Temporal CRAC channel blockade modulates[...]

Early and Maintained Treat-to-Target Response with Ixekizumab up to 5 Years in Moderate-to-Severe Psoriasis: Analysis of the UNCOVER-3 Study

Armstrong A, Merola JF, Chughtai R, Fotiou K, Ngantcha M, Sabatino S, Megna M, Man X, Honma M, Carrascosa JM, Pinter A. Early and Maintained[...]

Letter: Patch Test Utilization by Provider Type in the U.S. Commercially Insured Population, 2014-2024: Dermatologists on the Decline

Smart K, Armstrong AW, Adler BL. Letter: Patch Test Utilization by Provider Type in the U.S. Commercially Insured Population, 2014-2024: Dermatologists on the Decline. Dermatitis. 2026 Sep[...]